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Introduction
There are many diseases nowadays. For example, the In-
ternational Classification of Diseases (ICD-10) developed 
by WHO in 1994, lists about 20 000 diseases. There are even 
more drugs in the world, and their number is increasing 
every year. It is very difficult for a modern doctor to keep 
track of innovations on the pharmaceutical market. He 
must know everything about the medicine: its belonging to 
a certain pharmacological group, its mechanism of action, 
take into account the indications and contraindications for 
its use, possible side effects. The doctor should know the 
form of release and dosage of this particular medicine.
Paracelsus said, “The dose makes the poison”.  The dos-
age is the key factor that determines the drug’s effect on the 
body.
The study of the pharmacokinetic properties of the drugs 
allows us to determine the optimal route of their adminis-
tration, which in the future contributes to a rational dosage 
for its use in medical practice. The information about the 
pharmacokinetic properties of drugs can clarify the indica-
tions and contraindications of their use. So, substances that 
easily penetrate the hematoplacental barrier should be used 
with caution during pregnancy. Antimicrobials that are ac-
tively excreted by the kidneys or accumulated in the liver are 
suitable for the treatment of urinary or biliary tract infec-
tions, respectively. The pharmacokinetics of drugs creates 
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Abstract
Background: Iron deficiency anemia (IDA) is a hematologic syndrome characterized by the deregulation of hemoglobin synthesis due to iron deficiency. 
During pregnancy, there is an increase of about six times of iron. A correlation between body mass index (BMI) and hemoglobin (Hb) in pregnant women 
with IDA during the treatment with “Sorbifer Durules” (SD) was evaluated.
Material and methods: A retrospective, cohort study. 40 medical cards of pregnant women diagnosed with IDA during the pregnancy and who were 
treated with SD: one tablet 2 times per day, were studied. The BMI and Hb levels were assessed in each trimester of pregnancy. The dynamic of Hb values 
was determined: ΔHbII-I – the difference between Hb values of the 2nd and of the 1st trimesters, ΔHbIII-II – the difference between Hb values of the 3rd 
and of the 2nd trimesters. Statistics: Pearson’s correlation coefficient.
Results: IDA was diagnosed in 15 out of 40 pregnant women in the 1st trimester of pregnancy (IDA1), in 19 – in the 2nd trimester (IDA2), in 6 – in the 
3rd trimester (IDA3). 7 pregnant IDA1 with normal body weight (BMI = 18,5-25 kg/m2) had ΔHbII-I=14,28 g/l, 8 pregnant IDA1 with grade I obesity 
(BMI=30-35 kg/m2) had ΔHbII-I=26,12 g/l. Pearson correlation coefficient between BMI in the 1st trimester of pregnancy and ΔHbII-I in pregnant IDA1: 
r=+0,617, p=0,014. The associations between BMI and ΔHb in pregnant IDA2 and IDA3 were negligible.
Conclusions: There is a substantial and significant association between BMI in pregnant women who developed IDA in the 1st trimester and Hb increase 
during the treatment with SD.
Key words: iron deficiency anemia, pregnancy, body mass index, hemoglobin.
the basis for a rational search for new drugs with the desired 
patterns of distribution in the body, with higher activity or a 
wider spectrum of action [1].
The modification of the pharmacokinetics of drugs oc-
curs due to important physiological changes in the mother’s 
body during pregnancy. It is important to understand the 
dose-response relationship for optimizing the safe and ef-
fective use of drugs, especially in such a vulnerable popula-
tion as pregnant women. The optimal dosage of drugs dur-
ing pregnancy should provide maximal therapeutic efficacy, 
while minimizing the risk of maternal and fetal toxicity [2].
The study of rational pharmacotherapy during pregnan-
cy is significant due to the limited possibilities of clinical 
research of drugs involving pregnant women, possible fetus 
complications, side effects of drugs on both the mother and 
the fetus. The need for drug support for a normal pregnancy 
is also a relevant issue [3].
According to various sources, 80% of women in Russia, 
83% in Brazil, 62% in the USA, take at least one drug during 
pregnancy [4]. The average number of drugs per 1 pregnant 
woman is 11 ± 5.3. 
The purpose of this study is to provide scientific evi-
dence for the relationship between the pharmacokinetics of 
drugs and their dosage in pregnant women.
It is important for the practicing physician to know the 
particularities of dosage of drugs during pregnancy, depend-
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ing on the principles of pharmacokinetics. The pharmaco-
kinetics of the drug depends on many factors: genetics, co-
existing diseases, physiological changes that the pregnant 
body undergoes. If these conditions are not taken into ac-
count, the risk of incorrect prescription of a drug dose is 
high. As a result, an insufficient pharmacological effect will 
occur in case of administering a small dose. Alternatively, 
in case of a larger dose, there is a danger of the effect of ac-
cumulation and an increased risk of side effects of the drug 
to appear. It is important to find the golden middle when 
setting the dose.
The features of the pharmacokinetics of drugs during 
pregnancy
Age, weight, body mass index, gender, race, ethnicity, re-
nal and hepatic functions, genetic polymorphism, concomi-
tant pathology, therapy, smoking, alcohol and nutrition – all 
these factors can contribute to the variability of the phar-
macological response [5]. Pregnancy is also a physiological 
state of the body in which the pharmacokinetics of drugs 
changes (fig. 1).
Fig. 1.  Pharmacokinetic changes during pregnancy [6].
The absorption of drugs is influenced by many factors, 
such as: acidity of the stomach, transit time of food, meta-
bolic and transport processes in the intestine. Nausea and 
vomiting, characteristic for the first trimester of pregnancy, 
can reduce the amount of drug available for absorption, so 
it is important to take the drug when nausea is minimal, 
for example, in the evening [2, 6]. During pregnancy, the 
production of gastric juice decreases and the secretion of 
mucus increases, as a result of which gastric pH increases to 
5.6, with normal values  of 1.5. Such changes can increase the 
ionization of weak acids (for example, acetylsalicylic acid) 
and reduce its absorption, but weak bases (for example, caf-
feine) will diffuse better, because they will not be ionized. 
Slowed intestinal motility and increased cardiac output im-
prove blood circulation in the intestine and increase drug 
absorption [7] and accelerate its onset of action [6].
The pressure of increased in size uterus on the pelvic 
veins and the inferior vena cava prevents the outflow of 
blood from the rectum, which can interfere with absorption 
during the rectal route of administration. An increase in the 
body fat during pregnancy is a cause of deregulation of drug 
absorption in subcutaneous administration. In contrast, 
airway absorption may increase due to an increase of tidal 
volume characteristic for pregnancy [2].
The distribution of drugs was also changed. The plasma 
volume increases by 42%, reaching a total of 3.5 liters, and 
in parallel there is an increase in the volume of fluid in all 
parts of the body. Edema, which at least one third of women 
experience during pregnancy, can add up to 8 liters to the 
volume of extracellular fluid [6]. An expansion of the ex-
tracellular fluid volume will increase the distribution vol-
ume for hydrophilic drugs, but will decrease the plasma 
concentration of the drug. An expansion of the extracellular 
fluid volume will increase the distribution volume for hy-
drophilic drugs, but will decrease the plasma concentration 
of the drug. During pregnancy, the volume of the fat depot 
increases by about 4 kg, so the distribution volume for lipo-
philic drugs also increases. 
It is known that the amount of plasma proteins changes 
both during normal pregnancy and in pathological condi-
tions. With a normal pregnancy, albumin concentration 
decreases on average by about 10% after 20 weeks and by 
13% after 32 weeks. The change of albumin’s concentration 
is important in the prescription of drugs such as phenytoin, 
valproic acid, carbamazepine. Another plasma protein such 
as α-1-glycoprotein, which is involved in the binding of be-
tamethasone, bupivacaine, lopinavir and lidocaine, is lower 
by 52% at the end of pregnancy (30–36 weeks of gesta- 
tion) [8].
A complex biological barrier appears – the placental 
barrier. Lipophilic compounds pass through it (by diffu-
sion). Ionized polar substances (e.g. Quaternary ammoni-
um salts) cross the placenta poorly. The placenta also has a 
P-glycoprotein transporter [9]. Glycoprotein P is expressed 
on the maternal side of the placental membrane of syncy-
tiotrophoblast. It removes xenobiotics and drugs from the 
circulatory system of the fetus into mother’s circulatory 
system and also prevents the passage of several substrates 
through the blood-brain barrier to the fetus: calcium chan-
nel blockers, statins, macrolides, and some cytostatics [10]. 
For example, in antiretroviral therapy in a pregnant woman 
in order to prevent fetal HIV infection, it is extremely im-
portant to know that HIV protease inhibitors (for example, 
saquinavir), being a substrate of glycoprotein P, do not cross 
the placenta and thus do not protect the newborn [11].
The deposition of drugs during pregnancy in some tis-
sues can lead to side effects. For example, tetracyclines bind 
to calcium and are deposited in bone tissue, contributing to 
impaired development of the skeleton of the fetus [12].
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The metabolism of drugs by the liver during pregnancy 
is increased, mainly due to the induction of enzymes, possi-
bly due to an increased level of hormones. Moreover, blood 
circulation in the liver does not change. This can lead to an 
increase in the excretion rate of these drugs (eg, theophyl-
line) [6].
The activity of cytochrome P (CYP) isoforms such as 
CYP3A, CYP2D6, CYP2C9 increases, as a result of this the 
period of action of the non-metabolized form of the drug 
decreases and the daily dose of certain drugs should be in-
creased: amlodipine, erythromycin [8]. However, each or-
ganism is individual. For example, in clinical practice, in 
connection with depression, pregnant women often take 
the antidepressant fluoxetine, which is metabolized by the 
CYP2D6 isoenzyme, the gene of which has a polymor-
phism. It was found that “slow CYP2D6 metabolizers” have 
adverse reactions during treatment with fluoxetine (seda-
tion, cardiotoxicity, arrhythmias, etc.) more often, which is 
explained by high concentrations of the drug in the blood. 
Therefore, before prescribing antidepressants to pregnant 
women, it is necessary to conduct genotyping to identify the 
carriage of allelic variants of the CYP2D6 gene [11].
However, the activity of CYP1A2 and CYP2C19 de-
creases, therefore, the daily dose of drugs such as clozapine, 
theophylline, ondansetron, clopidogrel, omeprazole should 
be reviewed. It is known that progesterone and pregnane-
diol, the concentration of which increases during pregnan-
cy, activate sulfation of a number of drugs, and vice versa 
they block the enzymes of UDP-glucuronyl transferase, 
which leads to a slowdown in glucuronidation in the second 
phase of metabolism for a number of drugs (for example, 
lamotrigine) [11].
Excretion of drugs by the kidney during pregnancy de-
pends on filtration, secretion and reabsorption. During the 
first trimester, the glomerular filtration rate increases by 
50% and continues to grow in the future. Little information 
about the effect of pregnancy on tubular secretion and drug 
reabsorption is available. An increase of tubular secretion 
during pregnancy for digoxin and amoxicillin has been re-
ported. The renal clearance of ampicillin, cefuroxime, cef-
tazidime, cefradine, cefazolin increases in the second and 
third trimester, compared to non-pregnant women [2]. In 
this case, a dose adjustment of the drug is required.
During pregnancy, hepatic blood flow increases, which, 
in association with decreased binding of drugs to proteins, 
leads to an increase in clearance and lowered plasma con-
centrations of drugs [2].
Medicines and the fetus
The problem of evaluating the effect of drugs on the 
course and outcome of pregnancy is one of the most com-
plex and least studied areas of clinical pharmacology. For 
most drugs, if they are not intended to treat complications of 
pregnancy and childbirth, for ethical reasons, special stud-
ies of their safety in pregnant women are not carried out. At 
the same time, most women use drugs of various pharmaco-
logical groups (antimicrobial, antianemic, painkillers, anti-
inflammatory, psychotropic, multivitamins, etc.) during the 
gestational period, however, the benefit / risk ratio of their 
use during pregnancy has not been established. 
The greatest danger poses the teratogenic effects of 
drugs, which are understood as anatomical malformations, 
impaired histogenesis with subsequent functional inferior-
ity of the fetal organs and systems. In the early 60s of the 
twentieth century, more than 1000 children with phoco-
megaly were born in Europe (congenital absence of upper 
(proximal) parts of the limbs; in this case, the hands or feet, 
and sometimes both of them, are connected to the body 
by means of short stump). That is when the relationship of 
this developmental malformation with the use of the tha-
lidomide tranquilizer during pregnancy was proven, i.e., the 
fact of drug teratogenesis was established. Preclinical stud-
ies of this drug, performed on several types of rodents, did 
not reveal its teratogenic properties. In this regard, in the 
absence of embryotoxic, embryoletal and teratogenic effects 
of the drug in the experiment still prefer not to recommend 
its use in humans during pregnancy until confirmation of 
the complete safety of such a drug after a statistical analysis 
of the results of controlled clinical trials of its use in preg-
nant women is performed [13].
Most countries use classifications of risk categories of 
drugs in pregnancy to indicate the potential risk of drugs 
to the fetus. The first of them was introduced in Sweden in 
1978, and the next was the FDA (Food and Drug Adminis-
tration) classification (1979), which was most widely used 
in the world. Based on FDA recommendations, the follow-
ing categories of drugs are distinguished depending on tera-
togenicity:
• Category A: drugs in this group are harmless to the 
fetus throughout the whole pregnancy period (potassium 
chloride, iron preparations, multivitamins, triiodothyro-
nine);
• Category B: experimental studies did not reveal terato-
genic effects, or complications observed in animals were not 
found in children whose mothers were taking drugs includ-
ed in this group (insulin, acyl salicylic acid, metronidazole);
• Category C: in animal studies, teratogenic or embryo-
toxic effects of the drug were detected, control tests were 
not carried out, or the effect of the drug was not studied 
(isoniazid, fluoroquinolones, gentamicin, antiparkinsonian 
drugs, antidepressants);
• Category D: the use of drugs carries a certain risk to 
the fetus, but the benefits of their use exceed the possible 
side effects (diazepam, doxycycline, kanamycin, diclofenac);
• Category X: the teratogenic effect of drugs of this group 
has been proven, their use is contraindicated before and 
during pregnancy (isotretinoin, carbamazepine, streptomy-
cin) [14].
Material and methods
A retrospective cohort study of 40 cards of pregnant 
women, which were received at the University Hospital of 
Primary Care from 2017 to 2018, was conducted.
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All women developed iron deficiency anemia (IDA) at 
a certain stage of pregnancy. IDA was confirmed by a he-
moglobin blood test. Blood hemoglobin (Hb) values below 
110 g/l. (trimesters I and II), in the trimester II – below 105 
g/l and up to 90 g/l indicate IDA I degree, IDA degree  II– 
hemoglobin – 70–89 g/l, IDA degree III – hemoglobin less 
than 70 g/l, according to WHO [15].
The incidence of pregnant with IDA depends on sev-
eral factors: age, nationality, socioeconomic status, eating 
habits, diagnosis criteria [16, 17]. The study examined the 
following personal data of pregnant women: the age of the 
pregnant woman, gestational age at the time of registration, 
gestational age at the time of diagnosis IDA, the number of 
pregnancy, height, weight (in each trimester), hemoglobin 
(in each trimester). The study also looked at whether the 
pregnant woman suffered from co-existing diseases, such 
as liver, cardiovascular, respiratory, gastrointestinal, endo-
crine, gynecological, autoimmune diseases. In addition, the 
intake of medications for IDA was taken into account: the 
name, the dosage, the frequency of administration, before / 
after meals, and other medications.
The indicators of the first trimester corresponded to 11-
12 weeks of pregnancy, the second – 23-24 weeks, the third 
- 32-33 weeks, in accordance with the antenatal visits of the 
pregnant woman to the clinic.
Additional calculations were performed to calculate the 
body mass index (BMI) of pregnant women in each trimes-
ter: BMI = weight (kg) /height (m)2.
Women were divided into groups according to BMI:
<18.5 kg/m2 – underweight.
18.5 – 25 kg/m2 – normal weight.
25 – 30 kg/m2 – overweight.
30 – 35 kg/m2 – obesity  class I.
35 – 40 kg/m2 – obesity class II.
> 40 kg/m2 – obesity class III.
Unfortunately, due to the lack of data, the gestational 
weight gain was not calculated since the weight prior to the 
pregnancy was not indicated in the medical cards.
The difference (increase) in hemoglobin between two 
trimesters was also calculated:
ΔHb m-n = Hbm – Hbn
The difference in BMI between trimesters was calcu-
lated:
ΔIMTm-n = BMIm – BMIn
SPSS STATISTICS and MICROSOFT OFFICE EXCEL 
programs were used for calculations.
Results
The following results were revealed after processing the 
data.
Pregnant women were grouped into the following age 
groups (fig. 2).
The pregnancy number among all examined pregnant 
women is indicated in fig. 3. In the 1st place – women who 
are pregnant for the second time, in the 2nd place – preg-
nant women for the first time, in the 3rd place – women 
expecting a third child. 
Fig. 2.  The age groups of pregnant women.
Most pregnant women are between the ages of 31-35 
years, a little fewer are between 26-30 years old, which may 
be explained by the achievement of a certain financial stabil-
ity and favorable conditions for the birth of children by this 
period of life. 
Fig. 3. Pregnancy number.
Two hundred and eighty-six women planning a preg-
nancy took part in a study conducted in Chisinau in 2010. 
The results of the study were summarized after childbirth. 
In conclusion, the author points out the following risk fac-
tors for the development of IDA in pregnant women: 1) 
meat consumption less than 1 time per week, 2) use of iron 
preparations less than 60 days during pregnancy, 3) low lev-
el of education, 4) three and more born children [18]. Note 
that 1/3 of the pregnant women in our study have already 
become mothers of many children. Why is IDA so common 
in pregnant women?
Iron deficiency (ID) is the most common malnutrition 
in the world [19] and the most common cause of anemia in 
pregnant women (up to 75%) [20]. According to the WHO, 
ID can be found in 3.6 billion people, among whom 2 billion 
people, that is, more than 30% of the world’s population, 
suffer from anemia. The highest need for iron is observed 
in children in their first years of life (about 1 mg per day), 
which is associated with high rates of development; in the 
puberty, especially in girls in connection with the onset of 
menstruation (about 2 mg / day); in women of childbear-
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ing age with monthly menstrual loss of iron (about 2.5 mg 
/ day), in pregnant women (in the first trimester, 0.8 mg / 
day, in the second trimester – 4.0-5.0 mg / day, in the third 
trimester – up to 6.3 mg / day) due to active growth and 
fetal formation [21]. In general, uncomplicated pregnancy 
and childbirth are accompanied by a loss of 650 mg of iron 
[22]. It takes at least 2-3 years to restore the reserves of 
iron spent during pregnancy, childbirth and lactation [23]. 
Iron reserves do not have time to replenish with repeated 
pregnancy, in the presence of additional risk factors. ID in 
pregnant women is dangerous both for maternal health: de-
creased performance, general weakness, gestosis, premature 
detachment of a normally located placenta [24], and for the 
fetus: the risk of premature birth, the birth of a low birth 
weight child and even inhibition of the postnatal physical 
and neuropsychic development of the child are increased 
[25, 26]. 
It is important to understand that it is impossible to 
cure the patient IDA only with products rich in iron, since 
in them iron is mainly in the trivalent form (Fe3+). But this 
does not mean that pregnant women should not be recom-
mended to enrich their menu with food containing such 
an important trace element [27]. It is necessary to pay at-
tention not so much to the amount of iron in the product 
as to the form in which it is presented. Iron is most effec-
tively absorbed from products of animal origin, in which it 
is contained in the form of a heme, identical to that which 
is part of hemoglobin [28, 29]. The heme iron is absorbed 
by intestinal enterocytes unchanged. Gem is found in beef 
tongue, liver, rabbit, turkey, chicken, beef, fish [29]. Plant 
products: beans, pumpkin and sesame seeds, whole grains, 
thyme, parsley, field salad, contain non-heme iron, which 
is absorbed much worse, as it is presented in the form of 
Fe3+ and Fe2+. Non-heme iron can be captured by cells of the 
intestinal mucosa only in the form of Fe2+ [28]. The intake 
of a large number of apples, pomegranates, carrots, beets, 
buckwheat, recommended earlier in the USSR, is not justi-
fied from the point of view of the limited absorption of iron 
from them [30].
It is impossible to eliminate IDA only by means of a diet, 
since the absorption of Fe from food is no more than 2.5 mg 
per day, while it is absorbed 15–20 times more from drugs 
[30].
Iron deficiency anemia (IDA) is a hematological syn-
drome characterized by impaired hemoglobin synthesis 
due to iron deficiency [31, 32] and, as a result, a decrease 
in the number of circulating red blood cells per unit blood 
volume is below normal for a given age and gender. IDA is 
hypochromic microcytic anemia, which is an independent 
nosological unit [33], but as a rule, IDA is associated with 
some disease or condition of the body that causes absolute 
iron deficiency. This gave some scientists reason to believe 
that IDA is always secondary, there is no idiopathic form of 
this disease [22].
Further in our study, concomitant diseases of pregnant 
women were identified (fig.4.). Gynecological pathology 
is a uterine fibroid, an ovarian cyst; autoimmune – vulgar 
psoriasis, autoimmune thyroiditis; endocrine – autoim-
mune thyroiditis, hyperthyroidism, hypothyroidism, type I 
diabetes mellitus; diseases of the respiratory system – bron-
chial asthma; cardiovascular diseases – varicose veins of the 
lower extremities, arterial hypertension of pregnant women, 
sinus tachycardia, WPW syndrome, hemorrhoids; liver dis-
ease – hepatitis B.
Fig. 4. Concomitant diseases during pregnancy.
As a result of counting, 19 out of 40 women suffered from 
concomitant pathology, which proves to us a high incidence 
of women of childbearing age with chronic diseases, which 
is probably one of the reasons for the development of IDA.
Pregnant women have been gaining weight for 9 months 
and BMI in each trimester has changed accordingly (fig. 5).
Fig. 5.  BMI dynamics in three trimesters of pregnancy.
Thirty-two women out of 40 in the last trimester of preg-
nancy had a body weight greater than normal, but neverthe-
less if we compare the body weight parameters of pregnant 
women with the presence of IDA (fig. 6), we can draw in-
teresting conclusions: during treatment with iron prepara-
tions, the best effect was observed in overweight women.
A prospective, cohort study of 100 pregnant women 
with different BMIs was conducted in Moscow, and doctors 
concluded that the higher the BMI, the less likely the devel-
opment of anemia in the third trimester [34].
Iron absorption increases to 30-60% of the total amount 
in the diet in women with obesity during pregnancy, since 
the iron depot is exhausted and there is an increase in the 
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rate of erythropoiesis, as well as a slowdown of intestinal 
motility, which is characteristic of the second half of preg-
nancy, which lengthens the absorption period.
It is generally accepted that there are three possible 
causes that can lead to ID and anemia in obesity: 1) nutri-
tional deficiency of iron, 2) an increase in the volume of cir-
culating blood due to the intensive development of adipose 
tissue and, as a consequence, an increased need for iron, 
3) the development of a chronic systemic inflammatory pro-
cess in obesity [35]. The most likely cause of IDA in preg-
nant women is iron deficiency due to increased body need.
WHO (2016) recommends oral supplements with a con-
tent of 30-60 mg of elemental iron daily for pregnant wom-
en with normal hemoglobin levels to prevent IDA [15]. The 
equivalent of 60 mg of elemental iron is 300 mg of iron sul-
fate, 180 mg of iron fumarate or 500 mg of iron gluconate.
Pregnant women with IDA are prescribed 120 mg of 
iron per day until the hemoglobin reaches 105–110 g / l 
[36, 37]. After normalizing hemoglobin levels, the pregnant 
woman continues to take iron as usual (60 mg per day). 
Weekly supplements taken for at least 12 weeks increase the 
iron content in the body, as can be judged by the increase in 
hemoglobin and serum ferritin. The daily use of iron prepa-
rations should be continued until the end of pregnancy, as 
well as the first 6 months of breastfeeding [27].
Iron-containing drugs are recommended to be taken 30-
40 minutes before meals, with 100 ml of water or juice. The 
medicine should not be washed down with tea, coffee, milk 
or taken with food, as they reduce the absorption of iron 
[27]. The tannin contained in tea negatively affects the ab-
sorption of iron from food [22].
It should be noted that iron medications in the intesti-
nal lumen interact not only with food components, but also 
with drugs (oxalates, tannins, antacids, tetracyclines, chlor-
amphenicol, penicillins), which complicates the absorption 
of iron [38, 39].
In the treatment of IDA, the study revealed:
1. Family doctors prescribed 100% of pregnant women 
an iron-containing drug according to WHO recommenda-
tions: Sulfate Fe2+ + Vitamin C in a proportion: 320 mg + 
60 mg (Sorbifer Durules) 1 tablet 2 times per day; and is-
sued free to insured pregnant women in accordance with 
the current Order No. 729/230A, issued on June 11, 2018 
by the Ministry of Health, Labor and Social Protection of 
the Republic of Moldova and the National Health Insurance 
Company [40].
2. The reception of ”Sorbifer Durules” was appointed 
before meals to all women, taken with a glass of water. How-
ever, after the appearance of nausea and discomfort in the 
epigastrium, the reception was postponed for after the meal 
to 11 pregnant women.
3. At the same time, other multivitamin and polymineral 
drugs were prescribed, such as Ojestan (folic acid, iodine, 
omega-3 fatty acids, vitamins E and D3), Prenatal (vitamins 
A, C, D3, E, B1, B2, B6, B12, B9, PP, iron, zinc, calcium).
Why was Sorbifer Durules preferred?
Firstly, the drug has an inherent delayed release, which is 
provided by the special Durules technology, when the active 
substance is contained in a biologically indifferent plastic 
matrix of a spongy structure. Iron is first released from the 
surface layer of the system, and then gradually from deeper 
layers. The empty carrier is destroyed and removed from 
the body. At the same time, the gastrointestinal mucosa is 
slightly irritated, due to the lower concentration of iron dur-
ing its delayed release. The release of the active substance 
occurs regardless of the pH of the gastrointestinal tract [22].
Secondly, side effects when taking iron medication vary 
in degrees inherent in almost every drug and are mani-
fested primarily by symptoms of gastrointestinal discom-
fort. These include a tendency to constipation or diarrhea, 
a change in the color of feces (black), nausea, heaviness in 
the epigastric region, and a metallic taste in the mouth [22, 
41]. In retard forms of Fe2+ and Fe3+ medication, side effects 
are minimal.
Thirdly, in the work of P. A. Vorobyov [42] it is indicated 
that prices for iron-containing drugs can vary 10-15 times, 
and therefore patients and doctors are concerned about the 
ratio of cost and the resulting positive effect of the therapy. 
As an example, an analysis of several iron-containing drugs 
is carried out, on the basis of which the author concludes 
that the preparation “Sulfate Fe + Vitamin C” (Sorbifer 
Durules) has the lowest cost of ferrous iron, therefore, this 
medication is the most economically feasible in terms of 
“cost-efficiency”.
The change in the number of pregnant women with IDA 
by trimester of pregnancy is indicated in fig. 6.
Fig. 6. The dynamics of IDA by trimester of pregnancy.
The largest number of pregnant IDA was observed in the 
second trimester, it includes women whose drug effect of 
Sorbifer Durules has not yet increased hemoglobin to nor-
mal levels in women with IDA detected in the first trimes-
ter, as well as newly discovered cases of IDA. In the second 
trimester, the stage of organ formation is very active in the 
growing fetus, as a result of which iron is used more inten-
sively than in the first and hemoglobin decreases in direct 
proportion to the decrease in the mother’s serum iron.
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Table 1
Correlation of BMII with ΔHb2-1 and ΔHb3-
Para-
meter
Me-
dium
Standard 
deviations
Pearson 
correlation 
(r)
Bilateral 
signifi-
cance (p)
N
BMI1 27.58 5.26 15
ΔHb2-1 20.6 9.14 +0.617 0.014 15
ΔHb3-2 3.86 7.53 +0.027 0.925 15
Note: we studied 15 cases of pregnant women who developed IDA in the 
first trimester and were prescribed treatment with iron-containing drugs.
Table 2
Correlation between ΔBMI2-1 and ΔHb2-1
Para-
meter
Me-
dium
Standard 
devia-
tions
Pearson 
correlation 
(r)
Bilateral 
signifi-
cance (p)
N
ΔBMI2-1 1.59 0.66 15
ΔHb2-1 20.6 9.14 -0.59 0.836 15
Table 3 
Correlation between ΔBMI3-2 and ΔHb3-2
Para-
meter
Me-
dium
Standard 
devia-
tions
Pearson 
correla-
tion (r)
Bilateral 
signifi-
cance (p)
N
ΔBMI3-2 1.7 0.91 15
ΔHb3-2 3.86 7.53 -0.318 0.247 15
 
Pearson correlation (r) is a two-dimensional measure-
ment of the bond strength between two variables. If an 
increase in the values of one variable corresponds to an 
increase in the values of another variable, then the relation-
ship is called direct (positive +); if an increase in the values 
of one variable corresponds to a decrease in the values of an-
other variable, then the relationship is inverse (negative -). 
To assess the strength of the correlation the Cheddock table 
is used (tab. 4). The lower the probability (p-level value), 
the higher the statistical significance of the result. The result 
is considered statistically significant if the p-level does not 
exceed 0.05. That is, if p <0.05, the correlation is significant, 
if p> 0.05, then the correlation is negligible.
We conclude that there is a positive (+), noticeable (r = 
0.617) statistically significant relationship p = 0.014, p <0.05 
between BMI1 and the increase in hemoglobin from the first 
to the second trimester of pregnancy (ΔHb2-1) while taking 
the drug “Sorbifer Durules” (tab. 1).
Further attempts to find a connection between ΔIMT2-1 
and ΔHb2-1, between ΔIMT3-2 and ΔHb3-2 were unsuccessful, 
since the bilateral significance in the first case is r = 0.836, 
and in the second case r = 0.247 and both of them have p > 
0.05, therefore, there is low significance (tab. 2, 3).
Moreover, among 15 women with IDA in the first tri-
mester of pregnancy, in pregnant women with normal 
weight (n = 7), the increase in hemoglobin over 3 months of 
treatment with Sorbifer Durules averaged 14.28 g/l, and in 
pregnant women with class I of obesity (n = 8) – 26.12 g/l., 
that is, almost 2 times more.
These results are comparable with other sources. Wom-
en with normal and low BMI have a longer duration of ane-
mia, even during treatment with Sorbifer Durules, as well as 
a slower increase in hemoglobin when taking iron supple-
ments, compared with overweight women [43].
Women, especially those with normal and low BMI, can 
be recommended to increase the dosage of “Sorbifer Du-
rules”: 2 tablets – 2 times a day, which may contribute to 
an increase in Hb levels to the corresponding trimester of 
pregnancy values.
The absorption of iron medication can be accelerated by 
the simultaneous administration of succinic, ascorbic, py-
ruvic, citric acids, as well as fructose, sorbitol, methionine 
and cysteine. Calcium, vitamins C, B12, gastric acid, pepsin 
and copper contribute to the absorption of iron, especially if 
they come from animal sources [44].
Conclusions
1. The physiological changes that develop during preg-
nancy have a significant effect on the pharmacokinetics of 
drugs, which is reflected in the need to make appropriate 
amendments in the dosage regimen.
2. With obesity during pregnancy, iron absorption in-
creases to 30-60% of the total amount in the diet, since the 
iron depot is exhausted and there is an increase in the rate of 
erythropoiesis, as well as a slowdown of intestinal motility, 
which lengthens the absorption period.
3. There is a positive, noticeable, statistically significant 
relationship between the BMI of pregnant women in whom 
IDA developed in the first trimester of pregnancy and the 
growth of hemoglobin during treatment with “Sorbifer Du-
rules”.
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